Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study

Victor C Kok, Jorng-Tzong Horng, Wan-Shan Chang, Ya-Fang Hong, Tzu-Hao Chang, Victor C Kok, Jorng-Tzong Horng, Wan-Shan Chang, Ya-Fang Hong, Tzu-Hao Chang

Abstract

Introduction: Previous studies have shown an association between gout and/or hyperuricemia and a subsequent increase in cardiovascular disease (CVD) outcomes. Allopurinol reduces vascular oxidative stress, ameliorates inflammatory state, improves endothelial function, and prevents atherosclerosis progression. Accordingly, we tested the hypothesis that a positive association between allopurinol therapy in gout patients and future cardiovascular outcomes is present using a population-based matched-cohort study design.

Methods: Patients aged ≥40 years with newly diagnosed gout having no pre-existing severe form of CVD were separated into allopurinol (n = 2483) and non-allopurinol (n = 2483) groups after matching for age, gender, index date, diabetes mellitus, hypertension, hyperlipidemia, and atrial fibrillation. The two groups were also balanced in terms of uric acid nephrolithiasis, acute kidney injury, hepatitis, and Charlson comorbidity index.

Results: With a median follow-up time of 5.25 years, the allopurinol group had a modest increase in cardiovascular risk [relative risk, 1.20; 95% confidence interval (CI), 1.08-1.34]. A Cox proportional hazard model adjusted for chronic kidney disease, uremia, and gastric ulcer gave a hazard ratio (HR) for cardiovascular outcomes of 1.25 (95% CI, 1.10-1.41) in gout patients receiving allopurinol compared with the non-allopurinol group. In further analysis of patients receiving urate-lowering therapy, the uricosuric agent group (n = 1713) had an adjusted HR of 0.83 (0.73-0.95) for cardiovascular events compared with the allopurinol group.

Conclusions: The current population-based matched-cohort study did not support the association between allopurinol therapy in gout patients with normal risk for cardiovascular sequels and beneficial future cardiovascular outcomes. Several important risk factors for cardiovascular disease, such as smoking, alcohol consumption, body mass index, blood pressure were not obtainable in the current retrospective cohort study, thus could potentially bias the effect estimate.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Study flowchart showing target population,…
Figure 1. Study flowchart showing target population, exclusion reasons, matching and follow-up details in this retrospective matched-cohort population-based study using Taiwan National Health Research Institute Database.
Figure 2. Kaplan-Meier cardiovascular event-free survival curves…
Figure 2. Kaplan-Meier cardiovascular event-free survival curves of gout patients treated with allopurinol and matched comparators of gout patients receiving no allopurinol.
At a median follow up of 5.25 years, the allopurinol therapy group harbored an increased hazard ratio of 1.25 (95% confidence interval, 1.10–1.41).

References

    1. Bhansing KJ, van Bon L, Janssen M, Radstake TR (2010) Gout: a clinical syndrome illustrated and discussed. Neth J Med 68: 352–359.
    1. Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 63: 3136–3141.
    1. Krishnan E, Pandya BJ, Chung L, Dabbous O (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis—data from a prospective observational cohort study. Arthritis Res Ther 13: R66.
    1. Kanbay M, Sanchez-Lozada LG, Franco M, Madero M, Solak Y, et al. (2011) Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant 26: 430–437.
    1. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A (2012) Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 59: 235–242.
    1. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811–1821.
    1. Ford ES (2011) Uric acid and mortality from all-causes and cardiovascular disease among adults with and without diagnosed diabetes: findings from the National Health and Nutrition Examination Survey III Linked Mortality Study. Diabetes Res Clin Pract 93: e84–86.
    1. Kok VC, Horng JT, Lin HL, Chen YC, Chen YJ, et al. (2012) Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord 12: 108.
    1. Erdogan D, Tayyar S, Uysal BA, Icli A, Karabacak M, et al. (2012) Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 28: 721–727.
    1. George J, Carr E, Davies J, Belch JJ, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114: 2508–2516.
    1. Muir SW, Harrow C, Dawson J, Lees KR, Weir CJ, et al. (2008) Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39: 3303–3307.
    1. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51–59.
    1. Stone PH (2011) Allopurinol a new anti-ischemic role for an old drug. J Am Coll Cardiol 58: 829–830.
    1. Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, et al. (2008) Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 97: 334–340.
    1. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, et al. (2013) High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 61: 926–932.
    1. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, et al. (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388–1393.
    1. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71: 600–607.
    1. Gotsman I, Keren A, Lotan C, Zwas DR (2012) Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 18: 694–701.
    1. Thanassoulis G, Brophy JM, Richard H, Pilote L (2010) Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 170: 1358–1364.
    1. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, et al. (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308: 1906–1914.
    1. Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT, et al. (2012) Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ 184: E804–809.
    1. Chang CW, Kok VC, Tseng TC, Horng JT, Liu CE (2012) Diabetic patients with severe sepsis admitted to intensive care unit do not fare worse than non-diabetic patients: a nationwide population-based cohort study. PLoS One 7: e50729.
    1. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, et al. (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49: 141–146.
    1. Needham DM, Scales DC, Laupacis A, Pronovost PJ (2005) A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 20: 12–19.
    1. Schneeweiss S, Maclure M (2000) Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 29: 891–898.
    1. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, et al. (2002) Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87: 229–234.
    1. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, et al. (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58: 820–828.
    1. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375: 2161–2167.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅